EWTX news

Edgewise Therapeutics reported Q3 2026 results and dosed the first patient in its Phase 2 EQUINOX-HFpEF trial. Additionally, positive CIRRUS-HCM Part D results for EDG-7500 may support a Phase 3 trial initiation by year-end 2026, keeping the pipeline on target.

Edgewise announced positive Phase 2 CIRRUS-HCM data for EDG-7500 and finalized the sale of sevasemten to Servier for up to $2.65 billion, significantly boosting its balance sheet and strategic focus.

Edgewise finalized the sale of its muscular dystrophy business to Servier for $1.55 billion upfront. The transaction provides financial flexibility to advance its cardiovascular pipeline.

Edgewise Therapeutics agreed to sell its sevasemten asset and muscular dystrophy business to Servier for $1.55 billion upfront plus up to $1.1 billion in milestone payments. The transaction allows Edgewise to strengthen its balance sheet and refocus on its cardiovascular pipeline including EDG-7500 …

Euronet Worldwide submitted an exhibit filing with the Securities and Exchange Commission. The filing appears to be a standard regulatory disclosure requirement for publicly traded companies.